ArticleNeuro-oncology advances
Population-based validation of the RANO categories for extent of resection in glioblastoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The RANO Resect group published the updated Methods: This population based retrospective cohort study included 470 consecutive patients treated at two centers in Norway and Sweden. None of the hospitals had a strategy to aim for supramarginal resections. Postoperative contrast-enhanced T1 and FLAIR volumes were used to group the patients according to the RANO categories. Cox models and Kaplan-Meier plots were used for survival analyses. We performed subgroup analyses of patients where the Stupp protocol was initiated, MGMT methylated tumors, and elderly patients (≥70 years). Results: Median overall survival was 16, 15, 11, and 6 months for the respective categories of supramaximal (Class 1), maximal (Class 2), submaximal resection (Class 3), and biopsy only (Class 4). Thirty-five patients (7.5%) were classified as Class 1, despite not aiming for resection beyond the contrast-enhancing tumor. This class had a median tumor volume of only 6 mL, smaller preoperative FLAIR volumes and was associated with improved survival compared to Class 2 (HR = 0.6, Discussion and Conclusion: The RANO categories were associated with survival, but survival was shorter and differences across categories were less than in the original study. Maximal and supramaximal resections were associated with longer survival. One fourth of complete resections were incidentally classified as supramaximal resections, and these patients had a favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.